Pilgrim’s Pride (PPC) Q3 operating profit falls 61% despite Just Bare sales growth as chicken prices weaken
Read More Pharma Industry News ESSA Pharma shareholders approve XenoTherapeutics acquisition as investors weigh biotech liquidation value ESSA securityholders back XenoTherapeutics acquisition with 99% approval—learn how this deal reshapes biotech exit models and investor sentiment. bySoujanya RaviOctober 7, 2025